Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
The company had submitted a comprehensive Corrective and Preventive Action (CAPA) plan in September 2022
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Subscribe To Our Newsletter & Stay Updated
